Back to Search Start Over

Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.

Authors :
Savarino, Stephen J.
McKenzie, Robin
Tribble, David R.
Porter, Chad K.
O'Dowd, Aisling
Cantrell, Joyce A.
Sincock, Stephanie A.
Poole, Steven T.
DeNearing, Barbara
Woods, Colleen M.
Hye Kim
Grahek, Shannon L.
Brinkley, Carl
Crabb, Joseph H.
Bourgeois, A. Louis
Kim, Hye
Source :
Journal of Infectious Diseases. 7/1/2017, Vol. 216 Issue 1, p7-13. 7p.
Publication Year :
2017

Abstract

<bold>Background: </bold>Tip-localized adhesive proteins of bacterial fimbriae from diverse pathogens confer protection in animal models, but efficacy in humans has not been reported. Enterotoxigenic Escherichia coli (ETEC) commonly elaborate colonization factors comprising a minor tip adhesin and major stalk-forming subunit. We assessed the efficacy of antiadhesin bovine colostral IgG (bIgG) antibodies against ETEC challenge in volunteers.<bold>Methods: </bold>Adults were randomly assigned (1:1:1) to take oral hyperimmune bIgG raised against CFA/I minor pilin subunit (CfaE) tip adhesin or colonization factor I (CFA/I) fimbraie (positive control) or placebo. Two days before challenge, volunteers began a thrice-daily, 7-day course of investigational product administered in sodium bicarbonate 15 minutes after each meal. On day 3, subjects drank 1 × 109 colony-forming units of colonization factor I (CFA/I)-ETEC strain H10407 with buffer. The primary efficacy endpoint was diarrhea within 120 hours of challenge.<bold>Results: </bold>After enrollment and randomization, 31 volunteers received product, underwent ETEC challenge, and were included in the per protocol efficacy analysis. Nine of 11 placebos developed diarrhea, 7 experiencing moderate to severe disease. Protective efficacy of 63% (P = .03) and 88% (P = .002) was observed in the antiadhesin bIgG and positive control groups, respectively.<bold>Conclusions: </bold>Oral administration of anti-CFA/I minor pilin subunit (CfaE) antibodies conferred significant protection against ETEC, providing the first clinical evidence that fimbrial tip adhesins function as protective antigens. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00221899
Volume :
216
Issue :
1
Database :
Academic Search Index
Journal :
Journal of Infectious Diseases
Publication Type :
Academic Journal
Accession number :
124181280
Full Text :
https://doi.org/10.1093/infdis/jix144